• Cardiogreen (Indocyanine Green): Precision for Cell Assays &

  2026-04-22

  Explore how Cardiogreen (Indocyanine Green, SKU B8315) addresses core challenges in cell viability, proliferation, and cytotoxicity workflows. This article delivers scenario-driven, evidence-based guidance, benchmarking Cardiogreen’s reproducibility, spectral performance, and validated protocol parameters for high-impact biomedical research.

• One-step TUNEL FITC Apoptosis Detection Kit: Applied Workflo

  2026-04-22

  The One-step TUNEL FITC Apoptosis Detection Kit delivers sensitive, reproducible detection of apoptosis in both tissue sections and cultured cells, streamlining DNA fragmentation assays for cancer and immunology research. This article highlights optimized experimental workflows, troubleshooting strategies, and unique insights from recent Hippo signaling studies to guide superior assay design.

• MLN4924 HCl Salt: Optimizing NEDD8-Activating Enzyme Inhibit

  2026-04-21

  MLN4924 HCl salt is revolutionizing neddylation pathway inhibition by enabling precise modulation of ubiquitin-mediated protein turnover. This article details advanced workflow strategies, troubleshooting insights, and the practical impact of recent findings for cancer biology and antiviral research.

• Synthetic Viability with ERCC1 Deficiency in Lung Cancer ICL

  2026-04-21

  Heyza et al. (2019) uncover how ERCC1-deficient lung cancer cells exhibit synthetic viability to interstrand crosslinks (ICLs), modulated by p53 status. Their findings clarify confounding variables in platinum-based chemotherapy response and inform future biomarker development strategies.

• Selective Clearance of Senescent Beta Cells in Type 1 Diabet

  2026-04-20

  Thompson et al. (2019) demonstrate that a subpopulation of pancreatic beta cells in both human and NOD mouse models of type 1 diabetes (T1D) become senescent and actively contribute to disease progression. The study reveals that pharmacological elimination of these Bcl-2-upregulated senescent cells preserves beta cell mass and prevents T1D onset, providing a mechanistic rationale for targeted senolysis in autoimmune diabetes.

• Stattic: STAT3 Inhibitor Applications in Cancer Research

  2026-04-20

  Stattic empowers researchers to selectively inhibit STAT3 signaling, advancing both mechanistic studies and translational workflows in cancer biology. Its robust efficacy in apoptosis induction and radiosensitization, especially within HNSCC models, sets a new standard for pathway dissection and therapeutic exploration.

• SMYD2 Inhibition Reverses Drug Resistance in Renal Cell Carc

  2026-04-19

  This study demonstrates that targeting the histone methyltransferase SMYD2 suppresses tumor progression and overcomes multidrug resistance in clear cell renal cell carcinoma (ccRCC) by downregulating miR-125b and P-glycoprotein. The findings offer a mechanistic rationale for integrating epigenetic modulation with established chemotherapeutic agents in research on treatment-resistant cancers.

• TAI-1 Hec1 Inhibitor: Precision Workflows for Cancer Researc

  2026-04-18

  TAI-1 sets a new benchmark as a potent, first-in-class Hec1 inhibitor, enabling targeted mitotic disruption and robust apoptotic cell death induction. This guide translates recent mechanistic discoveries and reference study insights into actionable workflows, troubleshooting strategies, and advanced applications across diverse cancer research models.

• 3-Bromopyruvate Induces Ferroptosis to Overcome Cetuximab Re

  2026-04-17

  This study demonstrates that co-treatment with 3-bromopyruvate and cetuximab can overcome both intrinsic and acquired resistance to cetuximab in colorectal cancer cells by triggering autophagy-dependent ferroptosis and apoptosis. Mechanistic insights highlight the restoration of FOXO3a signaling as central to these effects, suggesting a promising therapeutic avenue for resistant colorectal cancer.

• Mubritinib–HSA Binding: Mechanistic Insights for Pharmacolog

  2026-04-16

  This study advances the understanding of how mubritinib, a mitochondrial complex I inhibitor with anti-cancer properties, interacts with human serum albumin (HSA). By employing multiple spectroscopic and molecular docking methods, the research elucidates key aspects of mubritinib’s binding affinity, site specificity, and resulting protein functional changes—findings relevant for drug development and optimizing pharmacokinetics.

• PSA-CD56/Siglec-7 Axis Drives Immune Evasion in ccRCC

  2026-04-15

  This study uncovers polysialylated CD56 (PSA-CD56) as a novel glyco-immune checkpoint in clear cell renal cell carcinoma (ccRCC), mediating immune evasion by engaging Siglec-7 on CD8+ T cells. The findings have significant implications for overcoming immunotherapy resistance and guiding apoptosis and necrosis detection strategies in translational research.

• GANT61 Triggers Apoptosis in ALK+ ALCL via Hh-PIK3IP1-Akt Ax

  2026-04-14

  This study elucidates how GANT61, a direct Gli1/2 inhibitor, suppresses proliferation and induces apoptosis in ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) by modulating the Hh-PIK3IP1-Akt signaling network. The findings provide mechanistic clarity on targeting the Hedgehog pathway and offer practical insight for designing apoptosis detection assays in hematologic malignancy research.

• Concanamycin A: V-type H+-ATPase Inhibitor in Cancer Workflo

  2026-04-13

  Concanamycin A empowers cancer biologists to probe V-ATPase signaling, apoptosis, and invasion mechanisms with nanomolar precision. This article details stepwise protocols and troubleshooting strategies, translating advanced research and the latest reference study into actionable insights for maximizing data quality.

• Methylprednisolone Sodium Succinate: Precision Dosing in Adv

  2026-04-13

  Explore the nuanced pharmacology and precision assay design potential of Methylprednisolone Sodium Succinate, a leading synthetic corticosteroid. This article delivers new insights on dosing, receptor dynamics, and translational research choices beyond typical mechanistic reviews.

• XPO1 Inhibition Reduces CRC Tumorigenesis via Wnt/β-Catenin

  2026-04-12

  This study demonstrates that Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, suppresses colorectal cancer (CRC) development by modulating the Wnt/β-catenin pathway. The findings underscore the mechanistic basis for XPO1 targeting as a chemopreventive strategy, offering translational insights for cancer research workflows.

13732 records 1/916 page Next 12345 下5页 Last page